12-24-2021: Wuhan, China: CAR T-cell therapy can't do without Actemra (tocilizumab): https://t.co/nwUES8eJBC https://t.co/lldOgjETIH https://t.co/e66VvfOjdl https://t.co/Eb7KpHBauD https://t.co/ktvwrEsQD6 https://t.co/QDxT5893Mj https://t.co/TPgAcTwpf2 h
RT @LaGonzalitas: @asepez Es odioso escoger la especialidad que salva al mundo de covid pero en el caso de tocilizumab y dexametasona, hay…
RT @LaGonzalitas: @asepez Es odioso escoger la especialidad que salva al mundo de covid pero en el caso de tocilizumab y dexametasona, hay…
@asepez Es odioso escoger la especialidad que salva al mundo de covid pero en el caso de tocilizumab y dexametasona, hay que otorgar ese honor a los oncólogos científicos que descubrieron su uso en casos de tormenta de citoquinas post-terapias de células T
'Spotlight on #Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date' an article on #ScienceOpen: #CARTT #Therapy @DovePress #OpenAccess https://t.co/YQ6yQFIMer
RT @CARTTherapy: Spotlight on Tocilizumab in the Treatment of #CAR-T-Cell-Induced #CRS Cytokine Release Syndrome: Clinical Evidence to Date…
RT @CARTTherapy: Spotlight on Tocilizumab in the Treatment of #CAR-T-Cell-Induced #CRS Cytokine Release Syndrome: Clinical Evidence to Date…
RT @CARTTherapy: Spotlight on Tocilizumab in the Treatment of #CAR-T-Cell-Induced #CRS Cytokine Release Syndrome: Clinical Evidence to Date…
Spotlight on Tocilizumab in the Treatment of #CAR-T-Cell-Induced #CRS Cytokine Release Syndrome: Clinical Evidence to Date https://t.co/Xw39t81Q3A